Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19

1 Jul 2020

Abstract excerpt

Background : Human coronavirus (SARS-CoV-2) is causing a pandemic with significant morbidity and mortality. As no effective novel drugs are available currently, drug repurposing is an alternative intervention strategy. Here we present an in silico drug repurposing study that implements successful concepts of computer-aided drug design (CADD) technology for repurposing known drugs to interfere with viral cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Pharmacological Effects of Natural Compounds
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32765844
DOI: 10.12688/f1000research.24143.1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19PMID 32765844Read ↗

Drug Repurposing for Covid-19: Discovery of Potential Small-Molecule Inhibitors of Spike Protein-ACE2 Receptor Interaction Through Virtual Screening and Consensus ScoringSemantic proximity Read ↗

Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants.Semantic proximity Read ↗

Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19Semantic proximity Read ↗

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposingSemantic proximity Read ↗

A new proposed mechanism of some known drugs targeting the SARS-CoV-2 spike glycoprotein using molecular dockingSemantic proximity Read ↗

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2Semantic proximity Read ↗

Phylogenetic analysis and In silico Screening of drug targets for ACE2 in Human and Spike Glycoprotein in Sars-CoV-2 for control of COVID19Semantic proximity Read ↗

In-silico analysis of potential interaction of drugs and the SARS-CoV-2 spike proteinSemantic proximity Read ↗

Structure Based Drug Repurposing Through Targeting Nsp9 Replicase and Spike Proteins of SARS-CoV-2Semantic proximity Read ↗

Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interfaceSemantic proximity Read ↗

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19Semantic proximity Read ↗

Emerging Strains Of SARS-Cov2 And Their Inhibition by The Use of Phytochemicals: An In-Silico AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.